Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Telescope Innovations Corp ( (TSE:TELI) ) is now available.
Telescope Innovations Corp reported its financial results for the second fiscal quarter of 2025, showing a revenue increase to $1 million but an adjusted EBITA loss of $0.4 million. The company is expanding its flagship product, DirectInject-LC™, into China and has hosted a successful user forum with Mettler Toledo, featuring major industry players like AstraZeneca and Genentech. Additionally, Telescope is advancing its Self-Driving Lab project in collaboration with Pfizer, which uses AI and robotics to accelerate pharmaceutical research. The company has also achieved a milestone in its Brine-to-Battery program, producing high-purity lithium carbonate, and its CTO, Jason Hein, received the prestigious 2025 R.U. Lemieux Award.
More about Telescope Innovations Corp
Telescope Innovations Corp is a developer of advanced technologies and services catering to the global pharmaceutical and chemical industries. The company focuses on creating innovative solutions like DirectInject-LC™ and ReCRFT™ to enhance process efficiency and support sustainable practices in these sectors.
YTD Price Performance: -36.59%
Average Trading Volume: 41,175
Technical Sentiment Signal: Buy
Current Market Cap: C$15.07M
See more insights into TELI stock on TipRanks’ Stock Analysis page.